Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 102

1.

Vaccine-Induced Memory CD8+ T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study.

Crosby EJ, Gwin W, Blackwell K, Marcom PK, Chang S, Maecker HT, Broadwater G, Hyslop T, Kim S, Rogatko A, Lubkov V, Snyder JC, Osada T, Hobeika AC, Morse MA, Lyerly HK, Hartman ZC.

Clin Cancer Res. 2019 May 1;25(9):2725-2736. doi: 10.1158/1078-0432.CCR-18-3102. Epub 2019 Jan 11.

PMID:
30635338
2.

Comparison between continuous and discrete doses for model based designs in cancer dose finding.

Diniz MA, Tighiouart M, Rogatko A.

PLoS One. 2019 Jan 9;14(1):e0210139. doi: 10.1371/journal.pone.0210139. eCollection 2019.

3.

Improving admission medication reconciliation with pharmacists or pharmacy technicians in the emergency department: a randomised controlled trial.

Pevnick JM, Nguyen C, Jackevicius CA, Palmer KA, Shane R, Cook-Wiens G, Rogatko A, Bear M, Rosen O, Seki D, Doyle B, Desai A, Bell DS.

BMJ Qual Saf. 2018 Jul;27(7):512-520. doi: 10.1136/bmjqs-2017-006761. Epub 2017 Oct 6.

4.

A Bayesian adaptive design for cancer phase I trials using a flexible range of doses.

Tighiouart M, Cook-Wiens G, Rogatko A.

J Biopharm Stat. 2018;28(3):562-574. doi: 10.1080/10543406.2017.1372774. Epub 2017 Oct 6.

5.

Critical evaluation of the Hirschsprung-associated enterocolitis (HAEC) score: A multicenter study of 116 children with Hirschsprung disease.

Frykman PK, Kim S, Wester T, Nordenskjöld A, Kawaguchi A, Hui TT, Teitelbaum DH, Granström AL, Rogatko A; HAEC Collaborative Research Group (HCRG).

J Pediatr Surg. 2018 Apr;53(4):708-717. doi: 10.1016/j.jpedsurg.2017.07.009. Epub 2017 Jul 14.

6.

Escalation with Overdose Control is More Efficient and Safer than Accelerated Titration for Dose Finding.

Rogatko A, Cook-Wiens G, Tighiouart M, Piantadosi S.

Entropy (Basel). 2015 Aug;17(8):5288-5303. Epub 2015 Jul 27.

7.

A Bayesian adaptive design for estimating the maximum tolerated dose curve using drug combinations in cancer phase I clinical trials.

Tighiouart M, Li Q, Rogatko A.

Stat Med. 2017 Jan 30;36(2):280-290. doi: 10.1002/sim.6961. Epub 2016 Apr 7.

8.

A Bayesian Adaptive Design for Combination of Three Drugs in Cancer Phase I Clinical Trials.

Tighiouart M, Li Q, Piantadosi S, Rogatko A.

Am J Biostat. 2016;6(1):1-11. doi: 10.3844/amjbsp.2016.1.11. Epub 2016 Aug 25.

9.

A randomized, placebo-controlled trial of late Na current inhibition (ranolazine) in coronary microvascular dysfunction (CMD): impact on angina and myocardial perfusion reserve.

Bairey Merz CN, Handberg EM, Shufelt CL, Mehta PK, Minissian MB, Wei J, Thomson LE, Berman DS, Shaw LJ, Petersen JW, Brown GH, Anderson RD, Shuster JJ, Cook-Wiens G, Rogatko A, Pepine CJ.

Eur Heart J. 2016 May 14;37(19):1504-13. doi: 10.1093/eurheartj/ehv647. Epub 2015 Nov 27.

10.

Combined Quantitative Assessment of Myocardial Perfusion and Coronary Artery Calcium Score by Hybrid 82Rb PET/CT Improves Detection of Coronary Artery Disease.

Brodov Y, Gransar H, Dey D, Shalev A, Germano G, Friedman JD, Hayes SW, Thomson LE, Rogatko A, Berman DS, Slomka PJ.

J Nucl Med. 2015 Sep;56(9):1345-50. doi: 10.2967/jnumed.114.153429. Epub 2015 Jul 9.

11.

Analysis of the bypass angioplasty revascularization investigation trial using a multistate model of clinical outcomes.

Zhang X, Li Q, Rogatko A, Tighiouart M, Hardison RM, Brooks MM, Kelsey SF, Kaul S, Bairey Merz CN.

Am J Cardiol. 2015 Apr 15;115(8):1073-9. doi: 10.1016/j.amjcard.2015.01.543. Epub 2015 Feb 2.

12.

A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non-Small Cell Lung Cancer.

Owonikoko TK, Ramalingam SS, Miller DL, Force SD, Sica GL, Mendel J, Chen Z, Rogatko A, Tighiouart M, Harvey RD, Kim S, Saba NF, Pickens A, Behera M, Fu RW, Rossi MR, Auffermann WF, Torres WE, Bechara R, Deng X, Sun SY, Fu H, Gal AA, Khuri FR.

Clin Cancer Res. 2015 Apr 15;21(8):1859-68. doi: 10.1158/1078-0432.CCR-14-1998. Epub 2015 Feb 11.

13.

Stromal fibroblast-derived miR-409 promotes epithelial-to-mesenchymal transition and prostate tumorigenesis.

Josson S, Gururajan M, Sung SY, Hu P, Shao C, Zhau HE, Liu C, Lichterman J, Duan P, Li Q, Rogatko A, Posadas EM, Haga CL, Chung LW.

Oncogene. 2015 May 21;34(21):2690-9. doi: 10.1038/onc.2014.212. Epub 2014 Jul 28.

PMID:
25065597
14.

miR-409-3p/-5p promotes tumorigenesis, epithelial-to-mesenchymal transition, and bone metastasis of human prostate cancer.

Josson S, Gururajan M, Hu P, Shao C, Chu GY, Zhau HE, Liu C, Lao K, Lu CL, Lu YT, Lichterman J, Nandana S, Li Q, Rogatko A, Berel D, Posadas EM, Fazli L, Sareen D, Chung LW.

Clin Cancer Res. 2014 Sep 1;20(17):4636-46. doi: 10.1158/1078-0432.CCR-14-0305. Epub 2014 Jun 24.

15.

Dose finding with drug combinations in cancer phase I clinical trials using conditional escalation with overdose control.

Tighiouart M, Piantadosi S, Rogatko A.

Stat Med. 2014 Sep 28;33(22):3815-29. doi: 10.1002/sim.6201. Epub 2014 May 13.

16.

Escalation with overdose control using time to toxicity for cancer phase I clinical trials.

Tighiouart M, Liu Y, Rogatko A.

PLoS One. 2014 Mar 24;9(3):e93070. doi: 10.1371/journal.pone.0093070. eCollection 2014.

17.

RANK- and c-Met-mediated signal network promotes prostate cancer metastatic colonization.

Chu GC, Zhau HE, Wang R, Rogatko A, Feng X, Zayzafoon M, Liu Y, Farach-Carson MC, You S, Kim J, Freeman MR, Chung LW.

Endocr Relat Cancer. 2014 Mar 4;21(2):311-26. doi: 10.1530/ERC-13-0548. Print 2014 Apr.

18.

Transferring inpatient rehabilitation facility cancer patients back to acute care (TRIPBAC).

Asher A, Roberts PS, Bresee C, Zabel G, Riggs RV, Rogatko A.

PM R. 2014 Sep;6(9):808-13. doi: 10.1016/j.pmrj.2014.01.009. Epub 2014 Jan 17.

PMID:
24440553
19.

Convergent RANK- and c-Met-mediated signaling components predict survival of patients with prostate cancer: an interracial comparative study.

Hu P, Chung LW, Berel D, Frierson HF, Yang H, Liu C, Wang R, Li Q, Rogatko A, Zhau HE.

PLoS One. 2013 Sep 16;8(9):e73081. doi: 10.1371/journal.pone.0073081. eCollection 2013.

20.

Inhibition of β2-microglobulin/hemochromatosis enhances radiation sensitivity by induction of iron overload in prostate cancer cells.

Josson S, Matsuoka Y, Gururajan M, Nomura T, Huang WC, Yang X, Lin JT, Bridgman R, Chu CY, Johnstone PA, Zayzafoon M, Hu P, Zhau H, Berel D, Rogatko A, Chung LW.

PLoS One. 2013 Jul 10;8(7):e68366. doi: 10.1371/journal.pone.0068366. Print 2013.

21.

The Integrated Web Portal for Escalation with Overdose Control (EWOC).

Wang H, Tighiouart M, Huang SC, Berel D, Cook-Wiens G, Bresee C, Li Q, Rogatko A.

Open Med Inform J. 2013 May 31;7:18-23. doi: 10.2174/1874431120130427001. Print 2013.

22.

A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies.

Harvey RD, Owonikoko TK, Lewis CM, Akintayo A, Chen Z, Tighiouart M, Ramalingam SS, Fanucchi MP, Nadella P, Rogatko A, Shin DM, El-Rayes B, Khuri FR, Kauh JS.

Br J Cancer. 2013 Mar 5;108(4):762-5. doi: 10.1038/bjc.2012.604. Epub 2013 Jan 15.

23.

Rifaximin for preventing acute graft-versus-host disease: impact on plasma markers of inflammation and T-cell activation.

Qayed M, Langston A, Chiang KY, August K, Hilinski JA, Cole CR, Rogatko A, Bostick RM, Horan JT.

J Pediatr Hematol Oncol. 2013 May;35(4):e149-52. doi: 10.1097/MPH.0b013e31827e56af.

PMID:
23274384
24.

Pure epithelioid PEComas (so-called epithelioid angiomyolipoma) of the kidney: A clinicopathologic study of 41 cases: detailed assessment of morphology and risk stratification.

Nese N, Martignoni G, Fletcher CD, Gupta R, Pan CC, Kim H, Ro JY, Hwang IS, Sato K, Bonetti F, Pea M, Amin MB, Hes O, Svec A, Kida M, Vankalakunti M, Berel D, Rogatko A, Gown AM, Amin MB.

Am J Surg Pathol. 2011 Feb;35(2):161-76. doi: 10.1097/PAS.0b013e318206f2a9.

PMID:
21263237
25.

Is the updated Schwartz formula appropriate for assessing renal function prior to hematopoietic stem cell transplantation?

Qayed M, Thompson A, Applegate K, Haight A, Rogatko A, Chiang KY, Horan J.

Pediatr Blood Cancer. 2010 Jul 15;55(1):199-201. doi: 10.1002/pbc.22506.

PMID:
20486187
26.

Phase II and coagulation cascade biomarker study of bevacizumab with or without docetaxel in patients with previously treated metastatic pancreatic adenocarcinoma.

Astsaturov IA, Meropol NJ, Alpaugh RK, Burtness BA, Cheng JD, McLaughlin S, Rogatko A, Xu Z, Watson JC, Weiner LM, Cohen SJ.

Am J Clin Oncol. 2011 Feb;34(1):70-5. doi: 10.1097/COC.0b013e3181d2734a.

27.

caGrid-Enabled caBIG Silver Level Compatible Head and Neck Cancer Tissue Database System.

Wang H, Bouzyk E, Kuehn A, Muller S, Chen Z, Khuri FR, Shin DM, Rogatko A, Tighiouart M.

Open Med Inform J. 2010 Sep 1;4:171-8. doi: 10.2174/1874431101004010171.

28.

Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer.

Borghaei H, Alpaugh K, Hedlund G, Forsberg G, Langer C, Rogatko A, Hawkins R, Dueland S, Lassen U, Cohen RB.

J Clin Oncol. 2009 Sep 1;27(25):4116-23. doi: 10.1200/JCO.2008.20.2515. Epub 2009 Jul 27.

29.

Mitochondrial DNA mutation stimulates prostate cancer growth in bone stromal environment.

Arnold RS, Sun CQ, Richards JC, Grigoriev G, Coleman IM, Nelson PS, Hsieh CL, Lee JK, Xu Z, Rogatko A, Osunkoya AO, Zayzafoon M, Chung L, Petros JA.

Prostate. 2009 Jan 1;69(1):1-11. doi: 10.1002/pros.20854.

30.

Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma.

Cohen SJ, Alpaugh RK, Palazzo I, Meropol NJ, Rogatko A, Xu Z, Hoffman JP, Weiner LM, Cheng JD.

Pancreas. 2008 Aug;37(2):154-8. doi: 10.1097/MPA.0b013e31816618ce.

PMID:
18665076
31.

Phase II Trial of Dolastatin-10, a Novel Anti-Tubulin Agent, in Metastatic Soft Tissue Sarcomas.

von Mehren M, Balcerzak SP, Kraft AS, Edmonson JH, Okuno SH, Davey M, McLaughlin S, Beard MT, Rogatko A.

Sarcoma. 2004;8(4):107-11. doi: 10.1080/13577140400009163.

32.

Sleep/Wake patterns of individuals with advanced cancer measured by ambulatory polysomnography.

Parker KP, Bliwise DL, Ribeiro M, Jain SR, Vena CI, Kohles-Baker MK, Rogatko A, Xu Z, Harris WB.

J Clin Oncol. 2008 May 20;26(15):2464-72. doi: 10.1200/JCO.2007.12.2135.

PMID:
18487566
33.

Translation of innovative designs into phase I trials.

Rogatko A, Schoeneck D, Jonas W, Tighiouart M, Khuri FR, Porter A.

J Clin Oncol. 2007 Nov 1;25(31):4982-6.

PMID:
17971597
34.

Phase I trial of preoperative hypofractionated intensity-modulated radiotherapy with incorporated boost and oral capecitabine in locally advanced rectal cancer.

Freedman GM, Meropol NJ, Sigurdson ER, Hoffman J, Callahan E, Price R, Cheng J, Cohen S, Lewis N, Watkins-Bruner D, Rogatko A, Konski A.

Int J Radiat Oncol Biol Phys. 2007 Apr 1;67(5):1389-93.

PMID:
17394942
35.

Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer.

Cohen SJ, Alpaugh RK, Gross S, O'Hara SM, Smirnov DA, Terstappen LW, Allard WJ, Bilbee M, Cheng JD, Hoffman JP, Lewis NL, Pellegrino A, Rogatko A, Sigurdson E, Wang H, Watson JC, Weiner LM, Meropol NJ.

Clin Colorectal Cancer. 2006 Jul;6(2):125-32.

PMID:
16945168
36.

Changing patterns of bone and brain metastases in patients with colorectal cancer.

Sundermeyer ML, Meropol NJ, Rogatko A, Wang H, Cohen SJ.

Clin Colorectal Cancer. 2005 Jul;5(2):108-13.

PMID:
16098251
37.

New paradigm in dose-finding trials: patient-specific dosing and beyond phase I.

Rogatko A, Babb JS, Tighiouart M, Khuri FR, Hudes G.

Clin Cancer Res. 2005 Aug 1;11(15):5342-6.

38.

Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma.

Kim ES, Kies MS, Fossella FV, Glisson BS, Zaknoen S, Statkevich P, Munden RF, Summey C, Pisters KM, Papadimitrakopoulou V, Tighiouart M, Rogatko A, Khuri FR.

Cancer. 2005 Aug 1;104(3):561-9.

39.

Flexible Bayesian methods for cancer phase I clinical trials. Dose escalation with overdose control.

Tighiouart M, Rogatko A, Babb JS.

Stat Med. 2005 Jul 30;24(14):2183-96.

PMID:
15909291
40.

UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan.

Carlini LE, Meropol NJ, Bever J, Andria ML, Hill T, Gold P, Rogatko A, Wang H, Blanchard RL.

Clin Cancer Res. 2005 Feb 1;11(3):1226-36.

41.

Phase II study of fludarabine and alpha-interferon in patients with low-grade non-Hodgkin's lymphoma.

Morris GJ, Millenson MM, Padavic-Shaller K, Wang H, Rogatko A, Clyde J, Boyd RL, Yeslow G, Halbherr T, Schilder RJ, Smith MR.

Haematologica. 2004 Dec;89(12):1484-91.

42.

Phase II study of paclitaxel and estramustine in patients with recurrent and refractory non-Hodgkin lymphoma.

Borghaei H, Millenson M, Schilder R, Alden M, Rogatko A, Wang H, Padavic-Shaller K, Smith MR.

Cancer. 2004 Nov 1;101(9):2034-41.

43.

Patient characteristics compete with dose as predictors of acute treatment toxicity in early phase clinical trials.

Rogatko A, Babb JS, Wang H, Slifker MJ, Hudes GR.

Clin Cancer Res. 2004 Jul 15;10(14):4645-51.

44.

Individualized patient dosing in phase I clinical trials: the role of escalation with overdose control in PNU-214936.

Cheng JD, Babb JS, Langer C, Aamdal S, Robert F, Engelhardt LR, Fernberg O, Schiller J, Forsberg G, Alpaugh RK, Weiner LM, Rogatko A.

J Clin Oncol. 2004 Feb 15;22(4):602-9.

PMID:
14966084
45.

Phase I and pharmacokinetic study of the farnesyltransferase inhibitor R115777 in combination with irinotecan in patients with advanced cancer.

Cohen SJ, Gallo J, Lewis NL, Alpaugh RK, Gentner L, Rogatko A, Yeslow G, Schol J, Verhaeghe T, Zannikos P, Palmer PA, Weiner LM, Meropol NJ.

Cancer Chemother Pharmacol. 2004 Jun;53(6):513-8. Epub 2004 Feb 3.

PMID:
14760509
46.

Measurable immune dysfunction and telomere attrition in long-term allogeneic transplant recipients.

Lewis NL, Mullaney M, Mangan KF, Klumpp T, Rogatko A, Broccoli D.

Bone Marrow Transplant. 2004 Jan;33(1):71-8.

PMID:
14704659
47.

Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?

Sharkey RM, Brenner A, Burton J, Hajjar G, Toder SP, Alavi A, Matthies A, Tsai DE, Schuster SJ, Stadtmauer EA, Czuczman MS, Lamonica D, Kraeber-Bodere F, Mahe B, Chatal JF, Rogatko A, Mardirrosian G, Goldenberg DM.

J Nucl Med. 2003 Dec;44(12):2000-18.

48.

Telomerase inhibition using azidothymidine in the HT-29 colon cancer cell line.

Brown T, Sigurdson E, Rogatko A, Broccoli D.

Ann Surg Oncol. 2003 Oct;10(8):910-5.

PMID:
14527910
49.

Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma.

Cohen SJ, Ho L, Ranganathan S, Abbruzzese JL, Alpaugh RK, Beard M, Lewis NL, McLaughlin S, Rogatko A, Perez-Ruixo JJ, Thistle AM, Verhaeghe T, Wang H, Weiner LM, Wright JJ, Hudes GR, Meropol NJ.

J Clin Oncol. 2003 Apr 1;21(7):1301-6.

PMID:
12663718
50.

Weekly bryostatin-1 in metastatic renal cell carcinoma: a phase II study.

Haas NB, Smith M, Lewis N, Littman L, Yeslow G, Joshi ID, Murgo A, Bradley J, Gordon R, Wang H, Rogatko A, Hudes GR.

Clin Cancer Res. 2003 Jan;9(1):109-14.

Supplemental Content

Loading ...
Support Center